Differential immunogenicity of BNT162b2 or ChAdOx1 vaccines after extended-interval homologous dual vaccination in older people
Research
[키워드] adenovirus vaccine
adenovirus-based
Analysis
antibody
Antibody Response
Antibody titre
blood sample
BNT162b2
BNT162b2 mRNA
boost
cellular
Cellular immune response
cellular response
ChAdOx1
ChAdOx1 vaccine
Clinical efficacy
clinical risk
COVID
detectable
Donor
electrochemiluminescence immunoassay
elicited
Evidence
extended interval
extended-interval
heterologous vaccine
homologous
Homologous vaccine
Humoral immunity
IFN-γ ELISPOT
immune response
immune senescence
induce
Infection
IQR
limit
median
Meta-analysis
mRNA
natural infection
objective
of BNT162b2
offer
Older
participant
Patient
platform
protocol
question
recipient
regimen
regimens
reported
response
Result
SARS-CoV-2
SARS-CoV-2 vaccine
second dose
shown
Spike protein
Spike-specific antibody
stability
supplementary material
T cell response
the median
vaccination
Vaccine
vaccine responses
vaccinee
were assessed
were measured
[DOI] 10.1186/s12979-021-00246-9 PMC 바로가기 [Article Type] Research
[DOI] 10.1186/s12979-021-00246-9 PMC 바로가기 [Article Type] Research